Palisade Bio
PALI
5 hedge funds and large institutions have $644K invested in Palisade Bio in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less funds holding
Funds holding: 6 → 5 (-1)
19% less capital invested
Capital invested by funds: $791K → $644K (-$147K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$195K |
| 2 |
Renaissance Technologies
New York
|
+$180K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.99K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$183K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$75K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$19K |
PALI Hedge Fund Activity: Q4 2019 in Review
5 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2019, worth a combined $644K — down 19% from $791K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PALI and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, adding an estimated $195K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $183K sold.
- 5 institutional investors held Palisade Bio (PALI) as of Q4 2019, down from 6 in Q3 2019.
- Funds reported $644K of Palisade Bio stock for Q4 2019, down 19% quarter-over-quarter.
- 2 funds opened new Palisade Bio positions in Q4 2019 and 3 closed out, a net change of -1 holder.
- The largest Palisade Bio buyer in Q4 2019 was Sabby Management, an estimated $195K added.
- The largest Palisade Bio seller in Q4 2019 was Hudson Bay Capital Management, an estimated $183K sold.
Based on aggregated 13F filings for Q4 2019.